Hematologic Complications of Tuberculosis.

Area of Science:

• Hematology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) significantly impacts hematologic cellular components and plasma coagulation.
• Metabolic pathways for iron, folate, and vitamin B12 are disrupted by TB.
• Hematologic changes can also arise from TB pharmacologic treatments.

Purpose of the Study:

• To review and update the known hematologic effects of tuberculosis and its treatment.
• To explore lesser-known hematologic manifestations of TB in patients with pre-existing hematologic conditions.
• To highlight recent advancements in TB imaging, pathophysiology, and immune response.

Main Methods:

• Literature review of existing studies on TB and hematology.
• Analysis of current research on TB pathophysiology and immune response.
• Examination of new therapeutic agents for drug-resistant TB and their hematologic implications.

Main Results:

• TB affects the production and lifespan of all blood cells.
• Coagulation factor abnormalities and metabolic derangements (iron, folate, B12) are observed.
• Pharmacological TB treatments can induce secondary hematologic changes.
• Uncommon TB manifestations in non-TB hematologic patients are noted.

Conclusions:

• Tuberculosis profoundly affects hematologic parameters and coagulation.
• Understanding these effects is crucial for managing TB patients, especially those with co-existing hematologic disorders.
• Ongoing research is advancing TB diagnostics, understanding of its mechanisms, and treatment options, with attention to hematologic safety.